BRIDGEWATER, N.J., June 05, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced that it will host an Investor Reception and webcast on Saturday, June 10 during the American Diabetes Association (ADA) 77th Scientific Sessions in San Diego. The reception will feature two key opinion leaders, Mark Peyrot, PhD, discussing medication therapy and challenges in facilitating implementation of Insulin therapy with patients who have diabetes and Martin Sarkar, DO, discussing how the V-Go ® Wearable Insulin Delivery device can address many of these challenges.
| Event: | Valeritas Investor Day Reception | |
| Date: | Saturday, June 10, 2017 | |
| Time: | 6:00 p.m. PDT |
Attendance at the event is open to institutional investors and equity analysts. If interested in attending the Investor Day, please reach out to Brian Johnston at bjohnston@theruthgroup.com to register. Note that registration is required to attend the event. A live webcast of the event will be available on the investor relations page of the Valeritas corporate website at www.valeritas.com and remain available for 90 days.
Participating Physicians
Mark Peyrot, PhD, is a Professor of Sociology at Loyola University Maryland and Professor of Health and Social Sciences at Bergen University College (Norway). Formerly, he was a faculty member in the departments of Sociology and Medicine at the University of Kentucky and Medicine at Johns Hopkins University. His recent projects comprise multiple funded studies, including: surveys of psychosocial and behavioral outcomes and determinants among diabetes patients, their family members and health care providers (e.g., the DAWN and DAWN2 studies); studies of patient reported outcomes in diabetes clinical trials (e.g., adherence, treatment satisfaction and quality of life); and studies of the drivers, consequences and relationships among diabetes, depression, and complications of diabetes. He has served leadership roles within ADA and AADE and was one of the developers of the AADE National Diabetes Education Outcome System, the AADE7 Self-care Behaviors, the ADA/AADE National Standards for Diabetes Self-management Education and the AADE National Standards for Outcomes Measurement of Diabetes Self-management Education. His 300+ publications include a co-edited collection of diabetes psychosocial care guidelines and a ADA position statement on diabetes psychosocial care recently published by ADA.
Martin Sarkar, DO, is a Staff Endocrinologist with Monocacy Health Partners Endocrine and Thyroid Specialists at Frederick Regional Health System in Frederick, MD. He received his medical degree from West Virginia School of Osteopathic Medicine, completed his internship and residency training in internal medicine at Eisenhower Army Medical Center, and completed his fellowship in endocrinology and metabolism at the Medical College of Georgia. He was previously Chief of Medicine and Medical Director of the Diabetes Clinic at Munson Army Medical Center - Fort Leavenworth, KS. Dr. Sarkar has been awarded many Army Commendation and Achievement medals as well as the Meritorious Service Medal for his service as Battalion Surgeon of the 3rd Infantry Division of the U.S. Army during Operation Iraqi Freedom. His clinical focus is in the management of diabetes, its complications and associated comorbidities. He has received multiple awards for excellence in patient care. He has been an investigator and sub-investigator for various research protocols for the Army Medical Corps and the Georgia Prevention Institute. He has numerous presentations regionally and nationally. Dr. Sarkar is on the speaker’s bureau for AstraZeneca, Medtronic, and Valeritas.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.